COSCIENS Biopharma Inc T.AEZS

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:AEZS - Post by User

COSCIENS Biopharma Inc > Important news on inflammation and cardiovascular disease

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jun 09, 2024 11:19am

36 Views

Post# 36079890

RE:Important news on inflammation and cardiovascular disease

Yes, the graph below shows a ~30-fold risk of cardiac death for 3-vessel inflammation, 13-fold for one artery, during extended follow-up

prophetoffactz wrote:

@EricTopol

The Big Miss in Cardiovascular Disease

Not diagnosing or getting on top of arterial inflammation in the new Ground Truths (link in my profile)

Yes, the graph below shows a ~30-fold risk of cardiac death for 3-vessel inflammation, 13-fold for one artery, during extended follow-up